Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Non-surgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness

Slide: 41 of 50

Other Report Findings of Adverse Effects

The rate of adverse effects increases with increased doses of darifenacin, fesoterodine, oxybutynin, and solifenacin. (Dosage effects of tolterodine and trospium are not reported.) The strength of evidence for this finding is high.

Transdermal and controlled-release forms of oxybutynin have lower rates of adverse effects, but a dose response for adverse effects is still found with these formulations. The strength of evidence for this finding is low.

Fifty percent of women stop treatment with drugs within 1 year. The strength of evidence for this finding is high.